Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)

• Company Description    Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.? Number of Employees: 229

• Price / Volume Information    Yesterday's Closing Price: $1.13 Daily Weekly Monthly 20 Day Moving Average: 3,095,319 shares Shares Outstanding: 221.88 (millions) Market Capitalization: $250.73 (millions) Beta: 0.36 52 Week High: $3.78 52 Week Low: $0.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.61% 3.75% 12 Week -12.40% -20.43% Year To Date -46.95% -50.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 210 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-457-2700 fax: - ir@allogene.com http://www.allogene.com

• General Corporate Information    Officers David Chang - President and Chief Executive Officer Arie Belldegrun - Executive Chairman Geoffrey Parker - Chief Financial Officer John DeYoung - Director Elizabeth Barrett - Director Peer Information Allogene Therapeutics, Inc. (CORR.) Allogene Therapeutics, Inc. (RSPI) Allogene Therapeutics, Inc. (CGXP) Allogene Therapeutics, Inc. (BGEN) Allogene Therapeutics, Inc. (GTBP) Allogene Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 019770106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 221.88 Most Recent Split Date: (:1) Beta: 0.36 Market Capitalization: $250.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 28.12% vs. Previous Quarter: 17.86% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -55.99 03/31/25 - -52.98 12/31/24 - -51.95 ROA 06/30/25 - -42.75 03/31/25 - -41.28 12/31/24 - -40.80 Current Ratio 06/30/25 - 8.92 03/31/25 - 9.71 12/31/24 - 8.54 Quick Ratio 06/30/25 - 8.92 03/31/25 - 9.71 12/31/24 - 8.54 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,168,850.00 Book Value 06/30/25 - 1.58 03/31/25 - 1.76 12/31/24 - 2.01 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©